A new trading day began on Friday, with Lineage Cell Therapeutics Inc (AMEX: LCTX) stock price down -4.12% from the previous day of trading, before settling in for the closing price of $0.63. LCTX’s price has ranged from $0.48 to $1.61 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 148.63% over the past five years. Meanwhile, its annual earnings per share averaged 8.33%. With a float of $219.47 million, this company’s outstanding shares have now reached $220.42 million.
Let’s look at the performance matrix of the company that is accounted for 75 employees. In terms of profitability, gross margin is 90.99%, operating margin of -260.7%, and the pretax margin is -229.91%.
Lineage Cell Therapeutics Inc (LCTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lineage Cell Therapeutics Inc is 0.43%, while institutional ownership is 47.63%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.14% during the next five years compared to 19.25% growth over the previous five years of trading.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Here are Lineage Cell Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.10 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Lineage Cell Therapeutics Inc (AMEX: LCTX) saw its 5-day average volume 1.27 million, a negative change from its year-to-date volume of 2.41 million. As of the previous 9 days, the stock’s Stochastic %D was 37.65%. Additionally, its Average True Range was 0.05.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 24.48%, which indicates a significant decrease from 39.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.41% in the past 14 days, which was lower than the 98.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5799, while its 200-day Moving Average is $0.8625. Nevertheless, the first resistance level for the watch stands at $0.6595 in the near term. At $0.7183, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.7600. If the price goes on to break the first support level at $0.5590, it is likely to go to the next support level at $0.5173. The third support level lies at $0.4585 if the price breaches the second support level.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
With a market capitalization of 132.40 million, the company has a total of 220,416K Shares Outstanding. Currently, annual sales are 8,950 K while annual income is -21,490 K. The company’s previous quarter sales were 3,780 K while its latest quarter income was -3,030 K.
